Global BRAFKinase Inhibitors Market, by Drug (Vemurafenib, Dabrafenib, Lifirafenib,and Encorafenib), by Indication (Metastatic Melanoma, Metastatic Lung Cancer,and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies,and Online Pharmacies), and by Region (North America, Latin America, Europe,Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 924.8Million in 2020 and is expected to exhibit a CAGR of 8.6% during the forecastperiod (2020-2027), as highlighted in a new report published by Coherent MarketInsights.
BRAF kinase inhibitors Market -Impact of Coronavirus (COVID-19) Pandemic
BRAF kinase inhibitor drugs arerequired for cancer patients at advanced stage, which might be delayed due topandemic. During this COVID-19 pandemic, surgery, chemotherapy, andimmunotherapy of metastatic cancer patients are being postponed or evencancelled. These BRAF kinase inhibitor drugs are a preferred treatment option,as these drugs increase the survival rate of metastatic cancer patients in acost-effective way. In September 2019, according to the data published in NCBI,the survival rate of a cancer patient increased by 67% who was under BRAFinhibitor plus MEK inhibitor combination therapy within last 12 months. Also,during this pandemic situation, demand for treatment of cancer patients withCOVID-19 infection has not reduced but the inadequate supplies of personalprotective equipment (PPE) for healthcare providers, limited hospital capacity,including intensive care units (ICUs), and lack of point-of-care testingdevices have negatively impacted the treatment of cancer patients to someextent.
The increasing number of productapprovals and launches, R&D activities, and collaboration and partnershipstrategies adopted by key players are major factors, which are expected todrive growth of the BRAF kinase inhibitors market during the forecast period.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/4240
The product approvals of advancedBRAF kinase inhibitors from regulatory bodies in the market is expected tocontribute significantly to the BRAF kinase inhibitors market growth. Forinstance, in July 2020, Roche announced that the U.S. Food and DrugAdministration (FDA) approved Tecentriq (atezolizumab) plus Cotellic(cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600mutation-positive advanced melanoma patients. The safety profile observed inthe Tecentriq combination was consistent with the known safety profiles ofindividual medicines.
New BRAF family kinase inhibitorsare being extensively researched to develop new drugs for the treatment ofmetastatic cancers. Thus, rising R&D activities is expected to propel theBRAF kinase inhibitors market growth over the forecast period. For instance,BeiGene Limited has its experimental RAF family kinase inhibitor lifirafenib(BGB-283) in the pipeline in Phase 1 trials for treatment of cancers includingBRAF gene mutations and KRAS/NRAS gene mutations. Furthermore, in May 2020, anew study published in the Journal of Clinical Oncology reported that in aPhase I trial, BeiGene's experimental RAF family kinase inhibitor lifirafenib(BGB-283) demonstrated promising activity in patients with KRAS-mutatednon-small cell lung cancer and BRAF-mutated melanoma, thyroid cancer, andovarian cancer.
Browse 34 Market Data Tables and32 Figures spread through 184 Pages and in-depth TOC on Global BRAF KinaseInhibitors Market, by Drug (Vemurafenib, Dabrafenib, Lifirafenib, andEncorafenib), by Indication (Metastatic Melanoma, Metastatic Lung Cancer, andOthers), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, andOnline Pharmacies), and By Region (North America, Latin America, Europe, AsiaPacific, Middle East, and Africa) - Forecast to 2027"
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/braf-kinase-inhibitors-market-4240
The rising adoption of inorganicgrowth strategies such as collaborations and partnerships by major companies isexpected to drive growth of the BRAF kinase inhibitors market. For instance, inJanuary 2015, Pierre Fabre and Array BioPharma Inc. (acquired by Pfizer Inc. inJuly 2019) announced a collaboration to globally develop and commercializeArray’s late-stage novel oncology products, binimetinib and encorafenib.Binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, are currentlyadvancing in three global Phase 3 trials for melanoma and ovarian cancer.Pierre Fabre has the exclusive rights to commercialize both products in allother countries, including Europe, Asia, and Latin America.
Key Takeaways of the BRAF KinaseInhibitors Market:
The BRAF kinase inhibitors marketis expected to exhibit a CAGR of 8.6% during the forecast period (2020-2027),owing to the increasing number of product approvals and launches by key players
Among drug type, the dabrafenibsegment is expected to hold a major revenue share in 2027, owing to theincreasing product launches of BRAF kinase inhibitors for treatment ofmetastatic cancers. For instance, in May 2018, the U.S. Food and DrugAdministration approved dabrafenib (TAFINLAR) and trametinib (MEKINIST) manufacturedby Novartis Pharmaceuticals Corp. as a combination treatment for patients withlocally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600Emutation.
Major players operating in theBRAF kinase inhibitors market include F. Hoffmann-La Roche AG, NovartisInternational AG, and Pfizer, Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/4240
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
